Janux Therapeutics (JANX) Q3 2026 earnings summary

Executive summary

• Clinical-stage immunotherapy pipeline spans TRACTr, TRACIr and ARM platforms, with four candidates in clinical evaluation and no product sales to date.

• First patient dosed in the JANX013 plus JANX007 Phase 1 combination study, the first clinical evaluation of the TRACIr platform.

• Q3 net loss narrowed to $21.6M from $24.3M YoY; 9M net loss narrowed to $67.9M from $81.7M.

• Cash, cash equivalents and short-term investments totaled $945.7M at September 30, 2026.

Financial highlights

• Q3 collaboration revenue was $9.3M vs. $10.0M YoY; 9M revenue was $23.3M vs. $10.0M, reflecting BMS revenue and no Merck revenue in 2026.

• Q3 R&D expense was $30.6M vs. $34.6M YoY; 9M was $88.4M vs. $94.3M.

• Q3 G&A expense was $10.0M vs. $10.6M YoY; 9M was $32.1M vs. $30.9M.

• Q3 operating expenses were $40.5M vs. $45.3M and operating loss was $31.3M vs. $35.3M; 9M operating expenses were $120.5M vs. $125.3M and operating loss was $97.2M vs. $115.3M.

• Q3 net loss was $21.6M vs. $24.3M; 9M net loss was $67.9M vs. $81.7M.

Outlook and guidance

• R&D expenses and operating losses are expected to rise substantially as clinical and preclinical programs advance; no product revenue is expected for the foreseeable future.

• Existing cash, cash equivalents and short-term investments are expected to fund anticipated operating expenses and capital expenditures for at least 12 months after the report date.

• Additional capital will be needed to advance candidates through regulatory approval; options include equity, debt, grants, collaborations and licenses.

• Initial JANX011 Phase 1 healthy-volunteer data scheduled for an investor webcast on November 9, 2026; additional JANX007 Phase 1b data expected at a medical congress in H1 2027.